BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1267 related articles for article (PubMed ID: 29474870)

  • 21. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
    Lee JH; Lee JH; Lim SN; Kim DY; Kim SH; Lee YS; Kang YA; Kang SI; Jeon MJ; Seol M; Seo EJ; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
    Bone Marrow Transplant; 2010 Mar; 45(3):450-7. PubMed ID: 19668236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.
    Tamari R; Chung SS; Papadopoulos EB; Jakubowski AA; Hilden P; Devlin SM; Goldberg JD; Perales MA; Ponce DM; Sauter CS; Maloy MA; Herman DY; Klimek V; Young JW; O'Reilly RJ; Giralt SA; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2106-2114. PubMed ID: 26187863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 26. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
    Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
    Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.
    Condorelli A; Frigeni M; Quaresmini G; Salmoiraghi S; Pavoni C; Grassi A; Raviglione M; Civini A; Putelli A; Lussana F; Finazzi MC; Algarotti A; Micò MC; Spinelli O; Rambaldi A
    Leuk Res; 2024 Jul; 142():107529. PubMed ID: 38820666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: improved outcomes for de novo disease.
    Andolina JR; Kletzel M; Tse WT; Jacobsohn DA; Duerst RE; Schneiderman J; Helenowski I; Rademaker A; Chaudhury S
    Pediatr Transplant; 2011 May; 15(3):334-43. PubMed ID: 21492354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
    Ustun C; Trottier BJ; Sachs Z; DeFor TE; Shune L; Courville EL; Holtan SG; Dolan M; Weisdorf DJ; Warlick ED
    Biol Blood Marrow Transplant; 2015 May; 21(5):866-72. PubMed ID: 25620751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
    Mishra A; Corrales-Yepez M; Ali NA; Kharfan-Dabaja M; Padron E; Zhang L; Epling-Burnette PK; Pinilla-Ibarz J; Lancet JE; List AF; Komrokji RS
    Am J Hematol; 2013 Jul; 88(7):566-70. PubMed ID: 23605934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
    de Witte T; Bowen D; Robin M; Malcovati L; Niederwieser D; Yakoub-Agha I; Mufti GJ; Fenaux P; Sanz G; Martino R; Alessandrino EP; Onida F; Symeonidis A; Passweg J; Kobbe G; Ganser A; Platzbecker U; Finke J; van Gelder M; van de Loosdrecht AA; Ljungman P; Stauder R; Volin L; Deeg HJ; Cutler C; Saber W; Champlin R; Giralt S; Anasetti C; Kröger N
    Blood; 2017 Mar; 129(13):1753-1762. PubMed ID: 28096091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes.
    Kröger N
    Semin Hematol; 2017 Jul; 54(3):154-158. PubMed ID: 28958289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34
    Tamari R; Oran B; Hilden P; Maloy M; Kongtim P; Papadopoulos EB; Rondon G; Jakubowski AA; Andersson BS; Devlin SM; Ahmed S; Popat UR; Ponce D; Chen J; Sauter C; Young JW; de Lima M; Perales MA; O'Reilly RJ; Giralt SA; Champlin RE; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2018 May; 24(5):1079-1087. PubMed ID: 29325829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Allogenic stem cell transplantation from genotypically HLA-identical siblings for 30 patients with myelodysplastic syndromes].
    Xu LP; Huang XJ; Liu KY; Chen H; Liu DH; Han W; Chen YH; Gao ZY; Lu J; Wang JZ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):518-21. PubMed ID: 17172123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
    Jentzsch M; Döhring C; Linke R; Hille A; Grimm J; Pönisch W; Vucinic V; Franke GN; Behre G; Niederwieser D; Schwind S
    Am J Hematol; 2019 Dec; 94(12):1344-1352. PubMed ID: 31495933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.